About Adheron Therapeutics
Adheron Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2006 by David Lee and Michael Brenner, and was acquired by Roche in October 2015. Disrupting cell adhesion to treat a variety of diseases. Adheron Therapeutics has raised $1.5 million across 1 funding round from investors including Roche. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is Adheron Therapeutics Inc. Its competitors include Biogen, Kymeratx and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Adheron is a company focused on leveraging pioneering technology that disrupts cell adhesion to treat a varietyof diseases. Adheron Therapeutics has developed a pioneering technology that disrupts immune cell adhesion through a cell surface protein called Cadherin-11 in order to develop potential treatments for a variety of inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrotic diseases. The lead asset, SDP051, a humanized monoclonal antibody targeting Cadherin-11, has completed Phase 1 of clinical development. Adheron announced on October 9, 2015 that they have agreed to be acquired by Roche
- Headquarters San Francisco, United States
- Founders David Lee, Michael Brenner
- Stage Acquired
- SectorsHealthcare
- Website adherontherapeutics.com
- Social LinkedIn
- Acquired by Roche (Oct 2015)
- Legal Name Adheron Therapeutics Inc
Funding Insights of Adheron Therapeutics
Adheron Therapeutics has successfully raised a total of $1.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.5 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.5M
- Total Rounds 1
- Last Round Seed β $1.5M
- First Round $1.5M
(Jul 2015)
All 1 funding rounds of Adheron Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2015 | $1.5M | Seed | β | β | β |
1 investors in total: 1 institutional.
Investors in Adheron Therapeutics
Adheron Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Roche.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for Adheron Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adheron Therapeutics
2 people are tracked at Adheron Therapeutics (2 in leadership).
| Name | Role | Group |
|---|---|---|
David Lee | Co-Founder | Leadership |
Michael Brenner | Co-Founder | Leadership |
Complete people profiles for Adheron Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Adheron Therapeutics
3 dated milestones of Adheron Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Adheron Therapeutics is founded.
- Funding First funding round of $1.5M.
- Exit Acquired by Roche.
Competitors of Adheron Therapeutics
Adheron Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Kymeratx and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Adheron Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Adheron Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Adheron Therapeutics
Adheron Therapeutics was founded in 2006 and raised its 1st funding round 9 years after it was founded.
Adheron Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Adheron Therapeutics is a funded company, having raised a total of $1.5M across 1 funding round to date. The company's 1st funding round was a Seed of $1.5M, raised on Jul 2015.
Adheron is a company focused on leveraging pioneering technology that disrupts cell adhesion to treat a varietyof diseases. Adheron Therapeutics has developed a pioneering technology that disrupts immune cell adhesion through a cell surface protein called Cadherin-11 in order to develop potential treatments for a variety of inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrotic diseases. The lead asset, SDP051, a humanized monoclonal antibody targeting Cadherin-11, has completed Phase 1 of clinical development. Adheron announced on October 9, 2015 that they have agreed to be acquired by Roche.
Adheron Therapeutics's top competitors include Kymeratx, PureTech Health and Biogen.
Adheron Therapeutics has 1 investor. Key investors include Roche.
Adheron Therapeutics operates through Adheron Therapeutics Inc.
Yes. Adheron Therapeutics was acquired by Roche in October 2015.
